Levo-Methasan (Levomethadone Hydrochloride)

Levomethadone acts as a full agonist at the mu‑opioid receptors in the central nervous system. By binding to these receptors, it blocks pain signals and restores opioid tone, which helps alleviate withdrawal symptoms in dependent individuals and produces analgesic effects for chronic pain.

The dosage of Levo-Methasan is individualized. A qualified prescriber determines the appropriate dose, frequency, and duration based on the patient’s medical history, level of opioid tolerance, and therapeutic objectives. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for levomethadone in pregnancy and lactation are limited. Clinicians must weigh the potential benefits against possible risks to the fetus or infant. If treatment is deemed necessary, it should be closely monitored, and alternative therapies may be considered when appropriate.

To request Levo-Methasan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Both levomethadone and methadone are long‑acting opioids used for dependence treatment and pain control. Levomethadone is the levorotatory enantiomer of methadone and may offer a more predictable pharmacokinetic profile, potentially resulting in fewer drug‑interaction issues, though clinical decisions depend on individual patient response and physician judgment.

Levo-Methasan should be stored at ambient temperature below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Levo-Methasan is administered orally as a tablet. The patient swallows the tablet whole with water, following the dosing schedule prescribed by the healthcare provider. It should not be crushed, chewed, or dissolved unless specifically instructed by a clinician.

The most serious risks include respiratory depression, which can be life‑threatening, especially in opioid‑naïve patients or when combined with other depressants; QT‑interval prolongation leading to cardiac arrhythmias; severe hypotension; and rare allergic reactions such as anaphylaxis. Immediate medical attention is required if these occur.

Levo-Methasan is contraindicated in patients with known hypersensitivity to levomethadone or any formulation components, those with severe respiratory insufficiency, uncontrolled asthma, or significant cardiac conduction disorders. Caution is also advised for individuals with severe hepatic impairment or a history of substance misuse without proper supervision.